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Background: Persistent dry cough is a well known unwanted effect of Angiotensin-Converting Enzyme inhibitors
(ACE-i). Animal studies have shown that the ACE-i zofenopril has a less tussigenic effect compared to the widely used
ACE-i ramipril. The aim of this study was to compare cough sensitivity to inhaled tussigens, as well as spontaneous
cough in response to the administration of zofenopril and ramipril in healthy volunteers; pharmacokinetic (PK) data of
both zofenopril and ramipril, as well as their respective active forms, zofenoprilat and ramiprilat, was also collected.
Methods: Forty healthy volunteers were enrolled in a randomized crossover study. Patients were administered
zofenopril calcium salt (test drug) coated tablets, 30 mg daily dose or ramipril (reference drug) tablets, 10 mg daily
dose, for 7 consecutive days in two periods separated by a 21-day wash-out period. Cough sensitivity to capsaicin
and citric acid was assessed as the concentration of each tussigenic agent causing at least 2 (C2) or 5 coughs (C5);
spontaneous cough was also monitored throughout the study. PK parameters of zofenopril, ramipril and their
active forms, were collected for each of the two study periods. Airway inflammation, as assessed by fractional exhaled
nitric oxide (FeNO) and bradykinin (BK) levels, were measured prior to and following each treatment period.
Results: Ramipril, but not zofenopril, increased (p < 0.01) cough sensitivity to both tussigenic agents as assessed by C2.
With citric acid, C5 values calculated after both ramipril and zofenopril administration were significantly (p < 0.05
and p < 0.01, respectively) lower than corresponding control values. With both ACE-i drugs, spontaneous cough
was infrequently reported by subjects.
Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values
(ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs.
ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).
Both ACE-i drugs did not affect BK plasma levels; in contrast, ramipril, but not zofenopril, significantly increased
control FeNO values (from 24 ± 9.6 parts per billion [PPB] to 33 ± 16 PPB; p < 0.01).
Conclusions: Zofenopril has a more favourable profile when compared to ramipril as shown by a reduced
pro-inflammatory activity and less impact on the cough reflex.
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Table 1 Demographic and clinical characteristics of the
40 healthy volunteers (23 females) who participated to
the study
General
Age (years) 37.4 ± 9.8
Height (cm) 170.5 ± 10.8
Weight (Kg) 71.2 ± 14.5
BMI (Kg/m2) 24.2 ± 3.2
Vital signs
Systolic BP (mmHg) 121 ± 9.5
Diastolic BP (mmHg) 78.1 ± 6.0
Heart rate (beats/min) 62.8 ± 8.4
Body temperature (°C) 36.4 ± 0.3
Respiratory rate (breaths/min) 10.7 ± 0.6
Data presented as mean ± SD or number and percentage in parentheses. BMI,
body mass index; BP, blood pressure.
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Angiotensin-Converting Enzyme inhibitors (ACE-i) were
originally developed to target hypertension but now have
additional clinical indications such as congestive heart
failure, left ventricular dysfunction, atherosclerotic vascu-
lar disease and diabetic nephropathy [1]. It is purported
that they alter the balance between the vasoconstrictive,
salt-retentive, and hypertrophic properties of angiotensin
II (Ang II) and the vasodilatory and natriuretic properties
of bradykinin (BK) and alter the metabolism of a number
of other vasoactive substances [1].
Zofenopril is indicated for the treatment of mild to
moderate essential hypertension and of patients with acute
myocardial infarction [2]. After oral administration, zofeno-
pril is completely absorbed and converted into its active
metabolite, zofenoprilat, which reaches peak blood levels
after 1.5 h [3]. The plasma ACE activity is suppressed by
74.4% at 24 h after administration of single oral doses of
30 mg zofenopril calcium, the usual effective daily dose.
Ramipril is indicated for the treatment of hypertension,
symptomatic heart failure, mild renal disease, for cardio-
vascular prevention and secondary prevention after acute
myocardial infarction. Based on urinary recovery, the
extent of absorption is at least 56%. Peak plasma con-
centrations of ramiprilat, the sole active metabolite of
ramipril, are reached 2-4 h after intake. The peak anti-
hypertensive effect of a single dose is usually reached
3-6 h after oral administration and usually lasts for
24 h [4].
Dry, persistent cough is a well-recognized side effect
of ACE-i, the mechanism of which is not completely
understood [5]. The incidence of ACE-i induced cough
is variable, and ranges between 3-35% among various
studies [5,6]. Interestingly, some lines of evidence seem
to suggest that coughing induced by the ACE-i zofenopril
has a lower prevalence compared to other ACE-i [5]. The
inflammatory mediators BK and substance-P are known
to be involved, since they accumulate in the upper respira-
tory tract or lung after the enzyme is inhibited and fails to
degrade them [6]. BK also stimulates the production of
prostaglandins which, when accumulating, also seem to
induce cough [6].
A study performed on guinea pigs showed that zofe-
nopril administration did not increase citric-acid in-
duced cough, as opposed to ramipril, which augmented
it by 40-60% [7]. Similar results were obtained in rabbits,
where ramipril, but not zofenopril, increased the cough
response induced by both mechanical and chemical airway
stimulation [8].
The aim of this study was to assess changes in the
sensitivity of the cough reflex, both spontaneous and
induced by tussigens, in healthy volunteers administered
with zofenopril and ramipril. This analysis was coupled
with the analysis of the pharmacokinetics (PK) of the twoadministered drugs, the collection of airway inflammation
data by means of a simple, non invasive method such as
the measurement of the fractional exhaled nitric oxide
(FeNO) and the assessment of serum BK.
Methods
Study subjects
The present study included male (n = 17) and female
(n = 23) healthy volunteers aged between 18 and 55 years
(Table 1). Pregnant or breast-feeding women, subjects
abusing alcohol or drugs, those using any prescription or
over-the-counter medication on a regular basis, history of
gastrointestinal, renal, hepatic, pulmonary or cardiovascu-
lar disease, epilepsy, asthma, diabetes, psychosis or glau-
coma, smokers of more than 10 cigarettes/day, subjects
with known allergy to ACE-i, and subjects following
abnormal diets or practicing vegetarians, since these
conditions may influence drug PK [9], were not eligible
for inclusion in the study. Self-reported medical condi-
tions were compared/cross referenced with previous
and current medical records. In addition, to minimize
potential confounder effects in FeNO measurement,
subjects could not consume fresh grapefruit or drink
caffeine-containing beverages from 24 h prior to and
until last blood sampling time after each administration, ab-
stain from smoking 24 h beforehand, avoid alcoholic bever-
ages and strenuous physical exercise. The study protocol
adhered to the recommendations of the Declaration of
Helsinki for Human Experimentation and was approved
by the local ethics committee; informed consent was ob-
tained from each participant.
Study design and treatments
This was a repeated-dose, balanced, two-sequence, two-
period, two-treatment, non-placebo controlled, randomized,
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ACE-i agents with similar characteristics and was per-
formed using an open design, blinding was not necessary.
Subjects were randomly assigned to receive zofenopril cal-
cium salt (test drug) coated tablets, 30 mg daily dose, or
ramipril (reference drug) tablets, 10 mg daily dose, for 7
consecutive days followed by a 21 (±2) day wash-out
period, after which another 7-day period would follow
where subjects would receive the other treatment
(Table 2). The administered doses were those used for
treatment of hypertension and which would yield a
similar percentage of responders [2,4].
Assessment of cough sensitivity
Capsaicin and citric acid cough challenges were per-
formed prior to and following each 7-day treatment
period (Table 2). Cough sensitivity was assessed as the
lowest capsaicin or citric acid concentrations causing
at least 2 (C2) or 5 coughs (C5), provided that cough
was still present following inhalation of the next tussi-
genic concentration [10]. C2 and C5 values were con-
verted to logC2 and logC5, respectively, for analysis.
Concentrations of both capsaicin and citric acid were
prepared according to standard procedures [10], nebulized
by a jet nebulizer (DeVilbiss 646, DeVilbiss Health Care
Inc., Somerset, PA) driven by compressed air (8 L/min),
and inhaled for 1 min during normal tidal breathing. Vol-
unteers undergoing cough challenges were specifically
instructed not to attempt to suppress coughs and not to
talk immediately after inhalation of the tussigenic agent.
In addition, subjects were given the following instruction:
“allow yourself to cough if you need to, and as much as
you need to”. Subjects were also requested to note on a
diary the occurrence of spontaneous cough during the
two 7-day treatment periods, using a verbal scale.Table 2 Study assessments and timetable
1st treatment period
Day(s) 1 2 3 4 5
Drug dosing x x x x x
Vital signs recordings x
Capsaicin and citric acid challenges x
Spontaneous cough recordings at home From day 1 to 7
FeNO measurementa x
Assessment of pre-dose PK parameters x x x
Assessment of post-dose PK parametersb
Pre-dose BK measurements x
Post-dose BK measurementsc
AE monitoring From day 1 to 7
FeNO, fractional exhaled nitric oxide; AE, adverse event; PK, pharmacokinetic; BK, b
post-dose; bBlood samples obtained 20', 40', 1 h, 1 h30', 2 h, 3 h, 4 h, 5 h, 6 h, 8 h,
1 h, 2 h, 4 h, 6 h, 10 h, 16 h, and 24 h after drug administration.Pharmacokinetic and bradykinin analysis
Blood samples for the measurement of PK parameters
and for BK determination were obtained at pre-dose and
after drug administration for each of the two study pe-
riods (Table 2). For both zofenopril and ramipril, and
their respective active forms, zofenoprilat and ramiprilat,
the lowest (Cmin) plasma concentration in the “τ” period
(i.e. the 24 h interval after drug administration on day
7), and the area under the curve of plasma concentration
(AUCss,τ ) in the period “τ”, were determined. Repeated
pre-dose PK variables determination was performed in
order to establish baseline variability.
Assessment of airway inflammation
Serial measurements of FeNO were performed at baseline
and following (1.5 h and 5.5 h ± 30 min) each 7-day treat-
ment period with ramipril or zofenopril (Table 2). FeNO
measurements were always performed before cough chal-
lenges using a standardized single-breath method with an
electrochemical analyzer (HypAir FeNO system, Medisoft,
Sorinnes, BE). Subjects were seated (with no nose clip),
and exhaled to residual volume, inserted the mouthpiece,
inhaled to total lung capacity, then exhaled for 10 seconds
at a constant flow rate of 0.05 L/s ± 10%. The end-point of
measurement was considered when a plateau of at least
4 seconds was observed. Exhalations were repeated after a
30-second period of relaxation until 3 independent FeNO
values with ≤10% variation were obtained [11].
Statistical analysis
Based on the results of previous investigations [12,13],
the sample size of 40 patients was chosen to design the
study to have a 90% statistical power of detecting a mean
change in capsaicin LogC5 of 1.64 μM with a LogC5
standard deviation of 1.91 μM.Wash-out 2nd treatment period
6 7 8-29(±2) 30 31 32 33 34 35 36
x x x x x x x x x
x x x
x x x
From day 30 to 36
x x x




From day 30 to 36
radykinin; a FeNO assessments were performed at pre-dose, 1.5 h and 5.5 h
10 h, 12 h, 16 h, 24 h after drug administration; c measurement performed 40',
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served after administration of the test and the reference
drug were compared by means of non-parametric analysis
of variance for repeated measures. Spontaneous cough oc-
curring during the two treatment periods was only quali-
tatively assessed, as the prevalence was expected to be low
or very low. AUCss,τ PK parameters were calculated from
the individual concentration-time data by using the
program WinNonlin software (Pharsight Corporation,
Mountain View, CA, USA) and summarized by treatment
by means of descriptive statistics, in order to determine
mean and standard deviation values. Paired t-test was used
to compare mean FeNO values recorded after administra-
tion of the test and the reference drug. Statistical analyses
were performed by using GraphPad Prism, version 3.02
(GraphPad Software, Inc. La Jolla, CA); sample size and
power calculations were performed by using a dedicated
software (nQuery Advisor, release 2.0, Los Angeles, CA).
A p value <0.05 was considered statistically significant.
Results
All subjects completed the study. Adverse events of mild
intensity were reported by 13 subjects (5 after ramipril
and 8 after zofenopril) and included headache, vomit,
backache and vertigo. Vital signs (blood pressure, heart
rate, body temperature, respiratory rate) were not sig-
nificantly affected by the two treatments.
Cough sensitivity
With capsaicin, mean (±SD) control LogC2 values ob-
served prior to zofenopril (0.81 ± 0.42 μM) and ramipril
(0.78 ± 0.41 μM) administration did not significantly differ
(Figure 1A). However, ramipril administration consistently
lead to an increase in cough sensitivity following inhaled
capsaicin, as shown by the significant reduction in LogC2
(0.33 ± 0.28 μM, p < 0.01) compared to control values.
In contrast, zofenopril administration resulted in only a
slight and non-significant decrease in capsaicin LogC2
(0.75 ± 0.40 μM).Overlapping results were observed
with capsaicin LogC5 values (Figure 1B). Prior to drug
administration, LogC5 values for zofenopril and ramipril
controls were similar (1.4 ± 0.72 μM and 1.3 ± 0.63 μM,
respectively); they were reduced to 1.3 ± 0.68 (non signifi-
cant, [ns]) after zofenopril and to 0.45 ± 0.38 μM (p < 0.01)
after ramipril treatment.
With citric acid, mean (±SD) control LogC2 values prior
to zofenopril and ramipril administration (1.85 ± 1.24 mM
and 1.80 ± 1.28 mM, respectively) did not significantly dif-
fer (Figure 1C). On the other hand, ramipril administra-
tion significantly increased cough sensitivity to inhaled
citric acid, as shown by the significant reduction in LogC2
(1.48 ± 1.09 mM, p < 0.01) compared to control values.
In contrast, zofenopril administration lead to only slight
and inconsistent changes in citric acid LogC2 values(1.81 ± 1.27 mM, ns). Control LogC5 values of zofeno-
pril and ramipril did not significantly differ (Figure 1D).
However, both zofenopril and ramipril significantly
decreased LogC5 values to citric acid, from 2.69 ±
1.88 mM to 2.51 ± 1.57 mM with zofenopril (p < 0.05)
and from 2.67 ± 2.01 mM to 2.23 ± 1.04 mM with ramipril
(p < 0.01). The reduction in citric acid LogC5 induced by
zofenopril did not significantly differ from that provoked
by ramipril.
During treatment with zofenopril, 7 volunteers out of
40 recorded at least 1 spontaneous coughing episode,
with a total of 36 distinct coughing episodes. With rami-
pril, 9 volunteers recorded at least 1 coughing episode,
with a total of 24 distinct coughing episodes.Pharmacokinetics
At baseline, plasma zofenopril or ramipril and their re-
spective active forms (zofenoprilat/ramiprilat) were
not detected (Figure 2); the time course of plasma con-
centration after administration of either zofenopril or
ramipril was qualitatively similar for both drugs and
their respective active forms (Figure 2). Mean (±SD)
AUCss,τ values (ng/ml x h) were 84.25 ± 34.47 for zofe-
nopril, 653.67 ± 174.91 for zofenoprilat, 47.40 ± 21.30
for ramipril, and 182.26 ± 61.28 for ramiprilat. Both
test and reference drugs Cmin was 0, whereas traces of
the active compounds were found, with Cmin values for
zofenoprilat and ramiprilat being 1 ± 1.29 and 1.25 ± 0.39
respectively.Airway inflammation
Mean (±SD) FeNO control values (expressed in parts
per billion, PPB) obtained prior to zofenopril (22 ± 12
PPB) and ramipril (24 ± 9.6 PPB) administration did
not significantly differ (Figure 3). Administration of
zofenopril lead to a slight and non-significant increase
in mean FeNO (26 ± 12 PPB), whereas administration
of ramipril resulted in marked increases in FeNO (33 ±
16 PPB) compared to both the corresponding control
condition and the mean FeNO values recorded follow-
ing zofenopril administration (p < 0.01 for both treat-
ments, Figure 3).Bradykinin analysis
Figure 4 shows the pooled BK plasma concentration/
time profiles of the 40 volunteers, obtained on day 7 of
either treatment period. No difference was found for BK
levels after administration of zofenopril or ramipril. Pre-
dose levels of BK on day 1 of either treatment period
were 0.44 ± 0.17 ng/ml and 0.42 ± 0.16 ng/ml, respectively
for zofenopril and ramipril, not different from pre-dose
levels on day 7.
Figure 2 Pooled plasma-concentration/time profiles of zofenopril/
ramipril (A) and zofenoprilat/ramiprilat (B) obtained in 40
volunteers. Data presented as mean ± SD.
Figure 1 Mean (±SD) Log values of the capsaicin (A, B) and the citric acid (C, D) concentration causing at least two (C2) and five (C5)
coughs recorded in control conditions (pre-treatment, cross hatched bars) and after a 7-day treatment (filled bars) with zofenopril
(blue bars) or ramipril (red bars) in 40 normal volunteers. *, p < 0.05; **, p < 0.01.
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The main findings from this study suggest that short-
term administration of therapeutic doses of zofenopril
and ramipril have a different impact on the functionality
of the cough reflex, with ramipril markedly affecting theFigure 3 Box and whiskers plots illustrating changes in fractional
exhaled nitric oxide (FeNO) recorded in control conditions
(pre-treatment) and after a 7-day treatment period with zofenopril
or ramipril in 40 normal volunteers. Data presented as median,
25th/75th percentiles and maximum/minimum recorded values. PPB,
parts per billion.
Figure 4 Pooled bradykinin plasma concentration/time profiles
of all volunteers obtained after administration of either
zofenopril, 30 mg (blue line) or ramipril, 10 mg (red line). Data
presented as mean ± SD.
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both capsaicin and citric acid, whereas zofenopril pro-
voked only a minimal, albeit significant, decrease in citric
acid C5. These results reinforce and extend similar obser-
vations previously obtained in animal models [7,8] and in
healthy volunteers [14]. Although coughing is a well rec-
ognized, unwanted effect of ACE-i drugs [6], the mechan-
ism by which these agents cause cough remains unclear.
The effect may be related to a cascade of effects beginning
with the accumulation of kinins, followed by arachidonic
acid metabolism and the production of nitric oxide [15].
ACE inhibition can block BK dehydrogenase, the enzyme
responsible for BK breakdown, and may lead to the accu-
mulation of BK in the airways. BK has many local effects,
including the release of histamine from mast cells, and
also interferes with locally produced neurotransmitters,
such as substance-P and neuropeptide-Y which are re-
leased by vagal C-fibres and are known to have irritant
effects on the bronchial mucosa and increase cough re-
sponses [8]. Another factor that has been reported to be
involved in cough induction is prostaglandin synthesis
in the airways, since prostaglandins act locally as in-
flammatory agents [16]. Prostaglandin E2 stimulates air-
way sensory fibres possibly involved in cough mediation
(as does BK), resulting in cough [17]. On the other
hand, treatment with a prostaglandin synthetase inhibi-
tor may alleviate cough in affected patients [18].
Other factors that may explain the observed differences
between zofenopril and ramipril in inducing cough reflex
may be attributed to differences in the pharmacokinetic
profiles and differences in the ability of tissue and blood
esterases to hydrolyse their active metabolites, zofenopri-
lat and ramiprilat respectively [19,20]. In this regards, a
previous study has shown that the ramiprilat-ACE com-
plex is very stable and dissociates more slowly comparedwith complexes formed by the enzyme and other ACE in-
hibitors [21].
Spontaneous cough after either ACE-i drugs was in-
frequently reported by subjects, likely because it may
take weeks or even months to develop ACE-i-associated
cough [5].
In the present study, BK levels did not differ after ad-
ministration of zofenopril or ramipril; thus the less tussi-
genic property of zofenopril compared to ramipril cannot
be explained by the elevated BK levels following ACE-i
administration. However, as shown in a previous in-vivo
study [22], the capability of zofenopril to stimulate the
production of prostaglandins, either directly or by inhibit-
ing BK metabolism, is less than that of other ACE-i.
It has also been previously shown that in normotensive
volunteers enalapril is capable of increasing FeNO within
a few hours [23]. Furthermore, it is unclear whether
‘ACEi-induced cough’ as a clinical problem is directly re-
lated to changes in FeNO, as the effects were not directly
evaluated in hypertensive patients, but only in healthy vol-
unteers. Evidence suggests that hypertensive patients have
reduced baseline FeNO levels [23,24] and did not show
FeNO increase in response to enalapril administration,
unlike normotensive subjects [23]. Additional studies in
hypertensive subjects are still needed to clarify this.
It is likely that the activation of sensory airway ter-
minal by ACE-i agents may result in an enhancement of
the cough reflex and, eventually, in a decrease of the
stimulus intensity required to evoke cough, thus explain-
ing the present findings of an increased cough sensitivity
in normal subjects under treatment with therapeutic
doses of ramipril. The fact that zofenopril affected cough
sensitivity to a much lesser extent compared to ramipril
is in keeping with the notion of a less pronounced
stimulatory effect on prostaglandin production and/or
inhibitory activity on BK breakdown by zofenopril [7].
Further studies on the co-administration of an ACE-i
and a COX inhibitor could help clarify the tussigenic
role of prostaglandins with and without ACE-i.
To our knowledge, this is the first study to evaluate
airway inflammation, as detected by a non invasive
method such as the assessment of FeNO, in normal
subjects undergoing short-term treatment with ACE-i.
Results show that ramipril, but not zofenopril, causes
airway inflammation. The same mechanisms as for
cough induction may also be invoked to account for a
lack of any significant change in FeNO observed following
zofenopril, but not ramipril administration in our subjects.
Again, this finding points to the possibility that these
agents must have a different impact on arachidonic acid
metabolism and BK breakdown.
In the present study we examined AUCss,τ values and
these were quantitatively higher with zofenopril/zofeno-
prilat compared to ramipril/ramiprilat. These data suggest
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zofenopril.
This study performed in normal subjects was planned
and carried out following the crossover two-treatment,
two-sequence, two-product design. This meant that all
subjects experienced both treatments, and the crossover
guaranteed a good degree of comparison of the two ACE-i,
namely zofenopril, test drug, and ramipril, reference drug
in this study.
A limitation of the present study is the absence of a
placebo arm, and the question arises as to whether the
observed differences in cough sensitivity and airway in-
flammation after ACE-i treatments are a true treatment
effect. A placebo effect has been observed in several
cough clinical trials, and up to 85% of the efficacy of
some cough medicines can be attributed to a placebo ef-
fect [25]. However, the presence of significant plasma
concentration levels of both ACE-i drugs points at the
possibility that the results obtained in the present study
are related to treatment, rather than to a placebo effect.
In conclusion, findings of the present study suggest
that zofenopril possesses a more favourable therapeutic
profile when compared to ramipril, mainly consisting of
a lower impact on the sensitivity of the cough reflex, as
detected by widely used laboratory methods, and lack of
a significant pro-inflammatory action at the level of the
airways. The more tolerable profile of zofenopril is
coupled with an equivalent or even better efficacy than
ramipril in the prevention and treatment of cardiovas-
cular diseases, as evidenced by several head-to-head
trials [26-28].
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